FeesSafety
Pluang+

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

Company Fundamentals
19 Oct 2026, 18:00 WIB
Eyepoint, Inc.
View Source
Neutral
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demonstrated significant benefits by reducing treatment frequency by 38%, with many patients requiring fewer supplemental injections and maintaining strong anatomical control. The drug also showed a favorable safety profile with redosing. EyePoint plans further analysis of combined trial data and continues to advance DURAVYU's development for diabetic macular edema (DME), with pivotal trial results expected in late 2027.

EyePoint's DURAVYU trial results provide context for health sector stocks. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 17:11 WIB: Of 150 priced US health stocks, 69 rose and 45 fell. Notable movers include CTXR at USD 0.48 (+4.13%), SANA at USD 2.33 (+2.64%), and CYTK at USD 63.50 (+2.50%). Typical hold times range from 17 to 24 days.

More News

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms both demonstrate robust revenue growth driven by digital advertising and AI integration, with Alphabet focusing on search and cloud services, and Meta on social media engagement. Alphabet reported $471.1 billion revenue an...

Market News
Bullish
16 minutes ago
Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Coinbase Global and Mastercard represent two paths in finance: crypto infrastructure versus traditional payments. Coinbase's revenue is tied to volatile crypto trading, showing a 26.6% revenue decline and a net loss of $701.6 million in the past year...

Market News
Neutral
29 minutes ago
Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

On December 9, three major events will influence the stock market: the Federal Open Market Committee (FOMC) is expected to raise interest rates, Broadcom will report its earnings with a focus on AI semiconductor revenue, and Micron will begin a large...

Market News
Neutral
39 minutes ago
Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Realty Income, a large net-lease REIT with over 15,500 properties, faces headwinds from rising interest rates which increase borrowing costs and pressure profits. However, the company has a strong track record of increasing dividends for 32 years and...

Market News
Bullish
54 minutes ago
DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App